Differential regulation of FGFR3 by PTPN1 and PTPN2

Aberrant expression and activation of FGFR3 is associated with disease states including bone dysplasia and malignancies of bladder, cervix, and bone marrow. MS analysis of protein‐phosphotyrosine in multiple myeloma cells revealed a prevalent phosphorylated motif, D/EYYR/K, derived from the kinase domain activation loops of tyrosine kinases including FGFR3 corresponding to a recognition sequence of protein‐tyrosine phosphatase PTPN1. Knockdown of PTPN1 or the related enzyme PTPN2 by RNAi resulted in ligand‐independent activation of FGFR3. Modulation of FGFR3 activation loop phosphorylation by both PTPN1 and PTPN2 was a function of receptor trafficking and phosphotyrosine phosphatase (PTP) compartmentalization. The FGFR3 activation loop motif DYYKK650 is altered to DYYKE650 in the oncogenic variant FGFR3K650E, and consequently it is constitutively fully activated and unaffected by activation loop phosphorylation. FGFR3K650E was nevertheless remarkably sensitive to negative regulation by PTPN1 and PTPN2. This suggests that in addition to modulating FGFR3 phosphorylation, PTPN1 and PTPN2 constrain the kinase domain by fostering an inactive‐state. Loss of this constraint in response to ligand or impaired PTPN1/N2 may initiate FGFR3 activation. These results suggest a model wherein PTP expression levels may define conditions that select for ectopic FGFR3 expression and activation during tumorigenesis.

[1]  M. Moran,et al.  Proteomic Analysis of the Epidermal Growth Factor Receptor (EGFR) Interactome and Post-translational Modifications Associated with Receptor Endocytosis in Response to EGF and Stress* , 2014, Molecular & Cellular Proteomics.

[2]  M. Mohammadi,et al.  Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation. , 2013, Structure.

[3]  Mingjie Zhang,et al.  Decorating proteins with "sweets" is a flexible matter. , 2013, Structure.

[4]  T. Tiganis,et al.  PTP1B and TCPTP – nonredundant phosphatases in insulin signaling and glucose homeostasis , 2013, The FEBS journal.

[5]  P. Bastiaens,et al.  Regulation of Signaling at Regions of Cell-Cell Contact by Endoplasmic Reticulum-Bound Protein-Tyrosine Phosphatase 1B , 2012, PloS one.

[6]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[7]  M. Tremblay,et al.  Protein-tyrosine Phosphatase 1B Modulates Early Endosome Fusion and Trafficking of Met and Epidermal Growth Factor Receptors* , 2011, The Journal of Biological Chemistry.

[8]  M. Moran,et al.  Global Proteomic Assessment of the Classical Protein-Tyrosine Phosphatome and “Redoxome” , 2011, Cell.

[9]  B. Neel,et al.  Substrate specificity of protein tyrosine phosphatases 1B, RPTPα, SHP-1, and SHP-2. , 2011, Biochemistry.

[10]  M. Tremblay,et al.  In control at the ER: PTP1B and the down-regulation of RTKs by dephosphorylation and endocytosis. , 2010, Trends in cell biology.

[11]  C. Guérin,et al.  Colocalization Analysis in Fluorescence Micrographs: Verification of a More Accurate Calculation of Pearson's Correlation Coefficient , 2010, Microscopy and Microanalysis.

[12]  C. Futter,et al.  Membrane contacts between endosomes and ER provide sites for PTP1B–epidermal growth factor receptor interaction , 2010, Nature Cell Biology.

[13]  M. Moran,et al.  Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition , 2009, Proceedings of the National Academy of Sciences.

[14]  Morag Park,et al.  Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. , 2009, American journal of physiology. Endocrinology and metabolism.

[15]  K. Anderson,et al.  The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations , 2009, Science Signaling.

[16]  N. Hacohen,et al.  Highly parallel identification of essential genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.

[17]  M. Tremblay,et al.  Regulation of the Met Receptor-tyrosine Kinase by the Protein-tyrosine Phosphatase 1B and T-cell Phosphatase* , 2008, Journal of Biological Chemistry.

[18]  Gordon B. Mills,et al.  Derailed endocytosis: an emerging feature of cancer , 2008, Nature Reviews Cancer.

[19]  J. Ivaska,et al.  The protein tyrosine phosphatase TCPTP controls VEGFR2 signalling , 2008, Journal of Cell Science.

[20]  M. Mann,et al.  Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors , 2008, Proteomics.

[21]  J. Wesche,et al.  Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis. , 2008, Molecular biology of the cell.

[22]  Ha Won Kim,et al.  Role of Protein Tyrosine Phosphatase 1B in Vascular Endothelial Growth Factor Signaling and Cell–Cell Adhesions in Endothelial Cells , 2008, Circulation research.

[23]  J. Bunkenborg,et al.  Quantitation of multisite EGF receptor phosphorylation using mass spectrometry and a novel normalization approach. , 2007, Journal of proteome research.

[24]  A. Schmid,et al.  Direct interaction between ER membrane-bound PTP1B and its plasma membrane-anchored targets. , 2007, Cellular signalling.

[25]  Steven P Gygi,et al.  A probability-based approach for high-throughput protein phosphorylation analysis and site localization , 2006, Nature Biotechnology.

[26]  M. Tremblay,et al.  T-Cell Protein Tyrosine Phosphatase (Tcptp) Is a Negative Regulator of Colony-Stimulating Factor 1 Signaling and Macrophage Differentiation , 2006, Molecular and Cellular Biology.

[27]  Cristina M Furdui,et al.  Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. , 2006, Molecular cell.

[28]  M. Tremblay,et al.  Protein tyrosine phosphatase 1B negatively regulates macrophage development through CSF-1 signaling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Chunaram Choudhary,et al.  Tyrosine Phosphorylation Regulates Maturation of Receptor Tyrosine Kinases , 2005, Molecular and Cellular Biology.

[30]  M. Tremblay,et al.  Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. , 2005, Current opinion in cell biology.

[31]  J. Rush,et al.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.

[32]  F. Haj,et al.  Coordinated Regulation of Insulin Signaling by the Protein Tyrosine Phosphatases PTP1B and TCPTP , 2005, Molecular and Cellular Biology.

[33]  P. Lievens,et al.  The Kinase Activity of Fibroblast Growth Factor Receptor 3 with Activation Loop Mutations Affects Receptor Trafficking and Signaling* , 2004, Journal of Biological Chemistry.

[34]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[35]  P. L. Bergsagel,et al.  Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. , 2004, Blood.

[36]  S. Trudel,et al.  Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma , 2004, British journal of haematology.

[37]  C. Heldin,et al.  Site-Selective Regulation of Platelet-Derived Growth Factor β Receptor Tyrosine Phosphorylation by T-Cell Protein Tyrosine Phosphatase , 2004, Molecular and Cellular Biology.

[38]  P. Lievens,et al.  The Thanatophoric Dysplasia Type II Mutation Hampers Complete Maturation of Fibroblast Growth Factor Receptor 3 (FGFR3), Which Activates Signal Transducer and Activator of Transcription 1 (STAT1) from the Endoplasmic Reticulum* , 2003, The Journal of Biological Chemistry.

[39]  N. Tonks,et al.  Regulation of Insulin Receptor Signaling by the Protein Tyrosine Phosphatase TCPTP , 2003, Molecular and Cellular Biology.

[40]  P. Herrlich,et al.  Identification of protein tyrosine phosphatases associating with the PDGF receptor. , 2003, Biochemistry.

[41]  Rolf Apweiler,et al.  Faculty Opinions recommendation of Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2003 .

[42]  P. Hornbeck,et al.  Phosphoprotein Analysis Using Antibodies Broadly Reactive against Phosphorylated Motifs* , 2002, The Journal of Biological Chemistry.

[43]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[44]  P. L. Bergsagel,et al.  The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. , 2002, Current opinion in hematology.

[45]  Peter J Verveer,et al.  Imaging Sites of Receptor Dephosphorylation by PTP1B on the Surface of the Endoplasmic Reticulum , 2002, Science.

[46]  A. Neri,et al.  Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations , 2001, Oncogene.

[47]  W. Kuehl,et al.  Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. , 2001, Blood.

[48]  D. Barford,et al.  Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. , 2000, Molecular cell.

[49]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[50]  B. Kemp,et al.  The Protein-tyrosine Phosphatase TCPTP Regulates Epidermal Growth Factor Receptor-mediated and Phosphatidylinositol 3-Kinase-dependent Signaling* , 1999, The Journal of Biological Chemistry.

[51]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[52]  S. Hubbard,et al.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.

[53]  N. Tonks,et al.  Epidermal Growth Factor Receptor and the Adaptor Protein p52Shc Are Specific Substrates of T-Cell Protein Tyrosine Phosphatase , 1998, Molecular and Cellular Biology.

[54]  M. Rocchi,et al.  A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. , 1997, Blood.

[55]  D. Donoghue,et al.  Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain , 1997, Molecular and cellular biology.

[56]  J. Chernoff,et al.  Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor. , 1997, The Biochemical journal.

[57]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[58]  D. Barford,et al.  Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Olefsky,et al.  Protein Tyrosine Phosphatase 1B Interacts With the Activated Insulin Receptor , 1996, Diabetes.

[60]  Joseph Schlessinger,et al.  Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism , 1996, Cell.

[61]  D. Donoghue,et al.  Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II , 1996, Molecular and cellular biology.

[62]  E. Fischer,et al.  COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus , 1995, The Journal of cell biology.

[63]  D. Barford,et al.  Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. , 1995, Science.

[64]  D. Rimoin,et al.  Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3 , 1995, Nature Genetics.

[65]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[66]  D. Church,et al.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[67]  A. Ullrich,et al.  Differential activities of protein tyrosine phosphatases in intact cells. , 1993, The Journal of biological chemistry.

[68]  J. Dixon,et al.  Substrate specificity of the protein tyrosine phosphatases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[69]  B. Posner,et al.  The dephosphorylation of insulin and epidermal growth factor receptors. Role of endosome-associated phosphotyrosine phosphatase(s). , 1992, The Journal of biological chemistry.

[70]  B. Sefton,et al.  Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells. , 1988, Oncogene research.